RHHBY - Roche Holding AG

Other OTC - Other OTC Delayed Price. Currency in USD
43.80
+0.37 (+0.85%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close43.43
Open43.10
Bid0.00 x 0
Ask0.00 x 0
Day's Range43.04 - 43.85
52 Week Range32.28 - 46.00
Volume1,330,198
Avg. Volume3,077,126
Market Cap299.26B
Beta (5Y Monthly)0.35
PE Ratio (TTM)28.53
EPS (TTM)1.54
Earnings DateN/A
Forward Dividend & Yield1.14 (2.62%)
Ex-Dividend DateMar 19, 2020
1y Target Est49.10
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Pharma Large And Mid-Caps Race Against COVID-19
    Benzinga

    Pharma Large And Mid-Caps Race Against COVID-19

    COVID-19 coronavirus made us realize that health should always be our top priority. Here are some companies working to make the world a better place after the pandemic. AbbVie Inc - Botox To The Rescue With unappreciated potential, the stock of this big drugmaker has stellar fundamentals. AbbVie Inc's (NYSE: ABBV) acquisition of Allergan brought the company over 120 additional products that generated more than $16 billion in revenues last year.There were a few bumps along the way, but AbbVie now has Botox, and sales are growing in cosmetics and therapeutics.J&J - Active On All Fronts Although Johnson & Johnson (NYSE: JNJ)'s share price is nearly where it was at the start of the year, there are many reasons why this stock is an 'evergreen' favorite. To start, it is the largest healthcare company in the world with tremendous resources.In March, it committed more than $1 billion to develop a COVID-19 vaccine. It is also setting up a manufacturing capacity to produce the vaccine even before clinical trials take place by September. The vaccine could be available for emergency use authorization by 2021 if all goes well, but its scientists are exploring the potential for existing drugs to treat COVID-19.One of the main reasons that this stock has been a favorite among investors is its diversification across the healthcare sector with three business segments. The company's pharmaceutical segment is its biggest growth driver but the other two segments, consumer health, and medical devices are also multibillion-dollar businesses.Merck - Entering The COVID-19 Arena Merck & Co Inc (NYSE: MRK) announced 3 deals to find new medicines and vaccines to help combat the coronavirus. What is also positive is that Merck grew its EBIT by 29% in the last year, and that should make it easier to pay down debt.Roche - Combining Drugs To Fight COVID-19 Roche Holding AG (OTC: RHHBY) announced it plans to test whether mixing the anti-inflammation drug Actemra, with anti-viral treatment remdesivir, might give better results in treating severe cases of COVID-19 pneumonia than remdesivir alone.Roche is hoping that by combining the two in a global study of 450 hospitalized patients worldwide, it will be able to offer doctors a one-two punch against the enemy that took 360,000 lives as it quickly contaminated 5.8 million people.Everyone is fighting for the same goal - and the world is cheering for them to reach the finish line as soon as possible!This article is not a press release and is contributed by Ivana Popovic who is a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure. Ivana Popovic does not hold any position in the mentioned companies. Press Releases - If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors - IAM Newswire accepts pitches. If you're interested in becoming an IAM journalist contact: contributors@iamnewswire.com Questions about this release can be sent to ivana@iamnewswire.comPhoto by Chokniti Khongchum from Pexels.See more from Benzinga * 4 Blue Chips That Lived Up To Their Title During the Pandemic * How Social Media Stocks Fared During The Pandemic * HP and Dell At Least Managed to Top Estimates(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs
    Benzinga

    The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs

    Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1) * Adaptimmune Therapeutics PLC - ADR (NASDAQ: ADAP) * Aileron Therapeutics Inc (NASDAQ: ALRN) (announced positive interim results for its Phase 1b/2 study of ALRN-6924 as an agent to protect patients against chemotherapy-induced toxicity) * argenx SE - ADR (NASDAQ: ARGX) * Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) * Cerus Corporation (NASDAQ: CERS) * Dynavax Technologies Corporation (NASDAQ: DVAX) (reacted to reports of partner Sinovac expressing confidence in its coronavirus vaccine) * Emergent Biosolutions Inc (NYSE: EBS) (announced $628-million dollar BARDA funding for rapid development of COVID-19 vaccine candidates) * Imara Inc (NASDAQ: IMRA) * Immunovant Inc (NASDAQ: IMVT) * Inari Medical Inc (NASDAQ: NARI) * Kala Pharmaceuticals Inc (NASDAQ: KALA) * MEI Pharma Inc (NASDAQ: MEIP) * Novo Nordisk A/S (NYSE: NVO) * Protara Therapeutics Inc (NASDAQ: TARA) * TFF Pharmaceuticals Inc (NASDAQ: TFFP) * Turning Point Therapeutics Inc (NASDAQ: TPTX) * Vermillion, Inc. (NASDAQ: VRML) * Y-mAbs Therapeutics, Inc (NASDAQ: YMAB)Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 1) * Ocugen Inc (NASDAQ: OCGN) (announced discontinuation of Phase 3 trial of OCU300 for ocular Graft vs. Host Disease)Stocks In Focus Roche's Cancer Therapy Combo Approved For Treatment-Naive Liver Cancer Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) said the FDA approved its Tecentriq in combination with Avastin for the treatment of people with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.Allena's Momentum Carries Through Ahead of Conference Presentation Allena Pharmaceuticals Inc (NASDAQ: ALNA) shares were surging ahead of the company's presentation at the Jefferies Virtual Healthcare Conference. The shares were higher in Monday's regular session, reacting to an initiation by H.C. Wainwright with a Buy rating and $10 price target.Analyst Edward White said the biopharma is an "undervalued enzyme therapeutic company."Following a 31.55% jump to $2.21 in Monday's regular session, Allena shares were rallying by 35.29% to $2.99 in Tuesday's premarket session. Esperion Shares Slip As Shareholder Lawsuit Accorded Class Action Status Esperion Therapeutics Inc (NASDAQ: ESPR) shares came under pressure after a federal district court accorded class action status to a lawsuit filed on behalf of investors, alleging the company issued misleading statements about its non-statin cholesterol-lowering drug Nexletol in a bid to artificially inflate the stock price.The stock fell after it was evident the drug did not have a clear path to regulatory approval, the lawsuit alleged.The stock slid 3.07% to $40.77 in after-hours trading.Related Link: The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight Pfizer To Invest Up To $500M Across Portfolio Of Clinical-Stage Biotechs Pfizer Inc. (NYSE: PFE) announced the establishment of the Pfizer Breakthrough Growth Initiative, through which the company said it will invest up to $500 million in biotechnology companies to help provide funding and access to its scientific expertise to ensure continuity of the biotechnology companies' most promising clinical development programs.Myovant Gains On NDA Submission For Drug Combo to Treat Menstrual Bleeding Sumitovant Biopharma said its affiliate Myovant Sciences Ltd (NYSE: MYOV) has submitted an NDA for the once-daily relugolix combo tablet, comprising relugolix 40 mg, estradiol 1 mg and norethindrone acetate 0.5 mg, for the treatment of women with heavy menstrual bleeding associated with uterine fibroids.The stock was trading 0.95% higher at $17.09 in the premarket session.Sanofi Announces European Nod For Multiple Myeloma Drug Sanofi SA (NASDAQ: SNY) said the European Commission has approved its Sarclisa in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.Aytu Retires $15M In Debt Aytu Bioscience Inc (NASDAQ: AYTU) said it has retired $15 million debt assumed in connection with its previously announced acquisition of Cerecor Inc's (NASDAQ: CERC) Commercial Portfolio.Bidding War For Tetraphase Heats Up Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) said a revised offer from Melinta received in response to another revised offer from another suitor, AcelRx Pharmaceuticals Inc (NASDAQ: ACRX), has been deemed a superior offer by its board.Melinta and AcelRx have been engaged in a bidding war to lap up Tetraphase, with both companies sweetening their respective bids a few times.The revised AcelRx offer received May 27 called for exchanging each unit of Tetraphase stock for $0.5872 in cash and 0.7409 AcelRx shares, representing $1.70 in upfront per share value, and one CVR, entitling the holders to receive potential payments of up to $16 million in cash upon the achievement of certain future Xerava net sales milestones starting in 2021.Melinta's most recent bid offered $39 million in cash,plus an additional $16 million in cash potentially payable under CVR to be issued in the proposed acquisition.In premarket trading Tuesday, Tetraphase gained 6.9% to $2.48, while AcelRx shares were surging higher by 6.3% to $1.35.Offerings OraSure Technologies, Inc. (NASDAQ: OSUR) said it has commenced an underwritten public offering of 8 million shares of its common stock.The stock slipped 4.32% to $13.51 in after-hours trading.Adaptimmune priced its underwritten public offering of 20.5 million shares of its ADSs at $11 each for gross proceeds of $225.5 million. The company expects the offering to close on or about June 4.Kaleido Biosciences Inc (NASDAQ: KLDO) priced its underwritten public offering of 4.75 million shares of its common stock at $7.50 per share. The company expects to raise gross proceeds of $35.6 million from the offering. All the shares are being offered by the company. The offering is expected to close June 4.The stock was trading 2.87% higher at $8.24 in the premarket session. Allogene Therapeutics Inc (NASDAQ: ALLO) priced its underwritten public offering of 11.702 million shares at $47 per share for gross proceeds of $550 million.The offering is expected to close on or about June 4.The stock fell 0.57% to $48.66 in after-hours trading.Guardant Health Inc (NASDAQ: GH) announced the commencement of a proposed underwritten public offering of 10 million shares of its common stock, of which 3 million shares are being offered by Guardant Health and 7 million by SoftBank Investment.The stock was up 0.1% at $48.99 premarket. G1 Therapeutics Inc (NASDAQ: GTHX) said it has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $100 million. The company plans to use the proceeds to fund commercialization and further development of trilaciclib, its first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy.Intellia Therapeutics Inc (NASDAQ: NTLA) said it has commenced an underwritten public offering of $75 million of shares of its common stock. All of the shares in the proposed offering are to be sold by Intellia.Intellia shares were trading 0.91% higher at $20.73 premarket Tuesday.Related Link: Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates See more from Benzinga * Pfizer Analyst Takes Stock Of Negative Breast Cancer Data, Pharma Giant's 2025 Goals(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GuruFocus.com

    AstraZeneca Ranked Most Inventive, Roche Most Innovative

    AbbVie was 2 in innovation for the second consecutive year and 7 in invention Continue reading...

  • GlobeNewswire

    FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer

    Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy. “We’re excited that today’s approval of Tecentriq in combination with Avastin for unresectable or metastatic hepatocellular carcinoma brings a cancer immunotherapy option to people with this aggressive form of liver cancer,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development.

  • Better Coronavirus Stock: Abbott Labs or Roche?
    Motley Fool

    Better Coronavirus Stock: Abbott Labs or Roche?

    They're both leaders in COVID-19 diagnostics testing and a whole lot more. But one stock appears to be the better pick right now.

  • Roche Starts Study on Actemra with Gilead's Drug for Coronavirus
    Zacks

    Roche Starts Study on Actemra with Gilead's Drug for Coronavirus

    Roche (RHHBY) commences a phase III study on Actemra with Gilead's remdesivir in hospitalized patients with severe COVID-19 pneumonia.

  • FDA Approves Genentech’s Tecentriq in Combination With Avastin for People With the Most Common Form of Liver Cancer
    Business Wire

    FDA Approves Genentech’s Tecentriq in Combination With Avastin for People With the Most Common Form of Liver Cancer

    Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

  • Pharma Stock Roundup: MRK, RHHBY Give Coronavirus Updates,SNY to Sell Stake in REGN
    Zacks

    Pharma Stock Roundup: MRK, RHHBY Give Coronavirus Updates,SNY to Sell Stake in REGN

    Merck (MRK), Glaxo (GSK) and Roche (RHHBY) make progress in coronavirus research efforts.

  • GlobeNewswire

    CHMP recommends EU approval of Roche’s Rozlytrek for people with NTRK fusion-positive solid tumours and for people with ROS1-positive, advanced non-small cell lung cancer

    ·Rozlytrek has shown durable responses across multiple tumour types, including cancer that has spread to the brain, and could become Roche’s first tumour-agnostic therapy.

  • GlobeNewswire

    Updated data demonstrate Roche’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer

    ALEX study is the first global phase III study to show a clinically meaningful benefit in overall survival at five years (62.5% with Alecensa), compared with crizotinib.

  • Texas Infections Jump 3.2%, U.S. Cases Increase: Virus Update
    Bloomberg

    Texas Infections Jump 3.2%, U.S. Cases Increase: Virus Update

    (Bloomberg) -- Texas sports leagues can have some fans attend games even as new coronavirus cases in the state climbed at amost twice the weekly average. Overall U.S. infections increased 1.2%.New York gave store owners the power to keep out customers for not wearing a mask. Securities regulators are scrutinizing public companies that got U.S. stimulus aid.The U.S. Veterans Administration is using less of a drug touted by President Donald Trump for Covid-19. Roche’s immune suppressor Actemra will be paired with Gilead’s antiviral remdesivir in a late-stage trial.Key Developments:Virus Tracker: Cases top 5.7 million; deaths over 358,000Why New York suffered when other cities were sparedIndia’s deaths exceed China’s as global hot spots shiftVaccine makers may need to infect subjects to get resultsLatin America now accounts for 40% of daily virus deathsHow can I get it? The evidence on transmission: QuickTakeSubscribe to a daily update on the virus from Bloomberg’s Prognosis team here. Click VRUS on the terminal for news and data on the coronavirus. For a look back at this week’s top stories from QuickTake, click here.San Francisco to Reopen Retail, Sports (5:10 p.m. NY)San Francisco, one of the first U.S. cities to close, is taking steps to reopen businesses, while stay-home orders remain in effect. Starting June 15, restrictions will be loosened on outdoor dining, indoor retail and certain outdoor activities like summer camps, Mayor London Breed said. Professional sports can resume, but without spectators.The city will open child care and outdoor museums June 1. In the next phase, scheduled for July 13, hair salons will open and indoor dining and real estate open houses will be permitted.Breed said a stay-at-home order remains in place indefinitely, and encouraged office workers to continue to telecommute. “This plan is being implemented, but we are still asking people to stay at home if at all possible,” she said.Texas Cases Jump; Fans Return to Stadiums (4:25 p.m. NY)Texas Governor Greg Abbott will let professional sports leagues play games in stadiums and outdoor arenas with fans, limited to 25% of capacity. Indoor sports events remain closed to spectators. New cases rose faster than the weekly average.Leagues must submit a health and safety plan for screening and regular testing of employees, players and contractors, according to a statement on the state’s website. Six feet (1.8 meters) of distance should be maintained in settings including locker rooms, break rooms, workout or practice facilities, and showers.Texas cases climbed 3.2%, almost twice the seven-day average, to 59,766, according to state health department data. New-case detections outpaced the 2.9% increase in testing and, in terms of raw numbers, the case count increased at the steepest daily rate since the pandemic began.Fatalities rose 2.5% to 1,601. Abbott has been dispatching so-called surge response teams to Amarillo and other hot spots to deal with outbreaks centered in facilities such as meatpacking plants.U.S. Cases Rise 1.2% (4 p.m. NY)Coronavirus cases in the U.S. increased 1.2% as compared to the same time Wednesday, to 1.71 million, according to data collected by Johns Hopkins University and Bloomberg News. That’s in line with Wednesday’s rate and the average of 1.3% over the past seven days. Deaths rose 1.4% to 101,129.New York had more than 366,000 cases and 23,600 fatalities as of May 27, according to Governor Andrew Cuomo. Hospitalizations are declining, and daily fatalities were below 100 for a fourth day, after peaking at more than 700 in April.Florida reported 53,285 cases, up 1.2% from a day earlier, below the average increase of 1.5% in the previous seven days, according to the state’s health department. Deaths reached 2,364, an increase of 1.9%.California cases rose 2.7% to 101,697 while deaths rose 2.3% to 3,973, according to the state’s website.Boston Marathon Canceled (3 p.m. NY)The Boston Marathon was canceled by the Boston Athletic Association, which in a tweet said a virtual event will be staged in September. All participants who signed up for the April 20 race will be offered a refund and can participate in a virtual event Sept. 7–14. Participants in the virtual race will run the marathon distance 26.2 miles and upload data to a fitness app.Mayor Marty Walsh, in a tweet, said the organizers “with our input and support” determined a one-day race isn’t feasible. “This kind of event would not be responsible or realistic on September 14 or any time this year,” he said.Chicago Lets Workers Return (2:55 p.m. NY)More than 130,000 Chicago workers will be permitted to return to work on Wednesday as the city begins to reopen its economy, Mayor Lori Lightfoot said Thursday. Industries permitted to open June 3, with specific safety guidelines in place, include office-based jobs, real-estate services, personal services such as salons and barber hops, and child-care centers.Italian Soccer to Restart June 20 (2:41 p.m. NY)Italy’s top soccer league will restart on June 20 after the national lockdown closed arenas, Sports Minister Vincenzo Spadafora said, according to newspaper La Repubblica. The decision was announced after Spadafora met with Prime Minister Giuseppe Conte and soccer officials, Repubblica said on its website.Premier League to Resumes in Mid-June (1:50 p.m. NY)The English Premier League set a provisional restart date of June 17, although Chief Executive Richard Masters said safety requirements must be met before soccer matches resume. The league has 92 outstanding matches for the season.The league will restart with Aston Villa facing Sheffield United at home with Manchester City playing against Arsenal. Matches will take place without fans. The BBC will broadcast games for free for the first time once matches resume, the network said separately.Egypt has Most Cases in One Day (1:30 p.m. NY)Egypt reported 1,127 new cases, the most for one day in the Arab world’s most populous nation, and 29 new deaths, the Health Ministry said.France Paves Way to Reopen (12:55 p.m. NY)France will lift domestic travel restrictions and let most bars, restaurants and museums reopen starting Tuesday following weeks of stringent controls to contain the epidemic. Officials said confinement measures were more effective than expected in combating the disease’s spread. “Freedom will finally become the rule again, and prohibition the exception,” Prime Minister Edouard Philippe said Thursday, following a cabinet meeting.In areas including Paris and the surrounding region, lifting curbs will be slower. Bars and restaurants will be able to open only outdoor spaces, and sports centers will not open until the next phase starting June 22.SEC Opens Inquiry on Stimulus (12:30 p.m. NY)The Securities and Exchange Commission has started an inquiry into companies that received U.S. stimulus funds, scrutinizing whether representations made in loan applications were consistent with disclosures in securities filings, according to three people familiar with the matter.The SEC’s enforcement division has sent letters to some companies that got funding from the Small Business Administration’s Paycheck Protection Program, asking for information about how the funds were being used and for copies of loan applications, these people said.One person said investigators may be focusing on companies whose dire condition qualified them for paycheck loans but whose financial disclosures prior to the outbreak didn’t reflect such vulnerability.VA Trims Use of Trump-Touted Drug (12:20 p.m. NY)The U.S. Department of Veterans Affairs is reducing its use of hydroxychloroquine to treat Covid-19 patients, Secretary Robert Wilkie told a House Appropriations Committee panel on Thursday. The VA’s use of the drug peaked at the same time it did in the rest of the nation after President Donald Trump touted its use in March despite a lack of clinical evidence that it works.“We started ratcheting it down when we went more to remdesivir and we went to the convalescent plasma,” Wilkie said. “Last week we only used it three times.”Some analyses have found hydroxychloroquine associated with more deaths in Covid-19 patients given the drug’s heart risks compared with patients who didn’t use the treatment. Wilkie said he relied on the intent of a so-called Right to Try law pushed by Trump and passed by Congress in 2018 meant to increase access to experimental drugs.“This Congress was very clear in saying that if people of sound mind ask to be given experimental treatments because that may be the last thing that separates them from life and death then we do that,” he said. “The other option is to do nothing.”Italy’s Death Lowest in 4 Days (12:15 p.m. NY)Italy reported 593 new cases on Thursday, a slight rise from from 584 a day earlier. New deaths were 70, the fewest in four days, down from 117 on Wednesday. The country’s death toll is 33,142.The government will weigh regional data at the end of the week before further relaxing containment measures with free movement within the country from June 3.Cuomo Expands Mask Order (12:03 p.m. NY)New York Governor Andrew Cuomo will sign an executive order that lets owners of private businesses deny entry to anyone who doesn’t wear a mask or face covering. “We’re giving the store owner the right to say, ‘If you’re not wearing a mask, you can’t come it,” Cuomo said at a Brooklyn news conference.Later in his briefing, Cuomo defended the new order, saying individuals “don’t have a right to expose the store owner to the virus” or the right “to expose other patrons in the store to the virus.”New cases rose 0.5%, up from the 0.4% one-week average.Florida Cases Rise Below Average (11:50 a.m.)Florida reported 53,285 Covid-19 cases on Thursday, up 1.2% from a day earlier, compared with an average increase of 1.5% in the previous seven days. Deaths among Florida residents reached 2,364, an increase of 1.9%.Moscow Revises Death Count Higher (11:10 a.m. NY)Moscow’s health department said deaths linked to Covid-19 in April more than doubled after the count was broadened to include direct as well as related cases. While 636 deaths are blamed on the pandemic, an additional 756 people died of other causes while testing positive, according to a statement. Using the new methodology, the Russian capital’s virus death rate rose to 2.8% from 1.4%, it said.The city said it’s following the World Health Organization’s recommendations from mid-April to record fatalities “where the disease caused, or is assumed to have caused, or contributed to death.” Moscow had 1,753 more deaths in April than the three-year average, an increase of 17%, the department said.Trump Acknowledges ‘Very Sad Milestone’ (9:37 a.m. NY)President Donald Trump on Thursday publicly acknowledged the death toll of the U.S. outbreak had reached 100,000.Port Authority to Seek Fed Aid (9:35 a.m. NY)The Port Authority of New York and New Jersey will seek a short-term loan from a Federal Reserve relief program aimed at buying bonds from local and state governments under stress from the pandemic. The agency faces a $3 billion loss over two years tied to a 97% drop in airport traffic, a 95% decline in PATH train ridership and a 40% cut in bridge and tunnel traffic, according to a statement issued after the board approved making the request.White House Scraps Eco Forecast (9:30 a.m. NY)The White House won’t issue a formal economic forecast that would show Covid-19’s impact, according to two people familiar with the matter. One said the administration lacks the data to meet the deadline for the forecast, and the other said the unprecedented nature of the pandemic makes a forecast impossible.The outlook is usually in the “mid-session review,” issued in July or August, as a follow up to the budget released in February.Poland Surprises With Third Rate Cut (9:07 a.m. NY)Poland unexpectedly lowered borrowing costs for the third time in three months to stem the economic damage from the pandemic. The National Bank of Poland reduced its benchmark interest rate to a record low of 0.1% from 0.5% on Thursday, following cuts of one percentage point in March and April. All 24 economists surveyed by Bloomberg predicted no change.Iceland’s Airport Testing Plan Hits Snag (9:03 a.m. NY)Iceland’s plans to test every passenger arriving at its international airport for Covid-19 has hit a snag, after it emerged that the island doesn’t have enough testing facilities. Opening up the country to foreign travelers is a crucial step to lift the economy, which is forecast to contract 9% this year.U.S. Jobless Rolls Shrink for First Time in Pandemic (9:01 a.m. NY)U.S. states’ jobless rolls shrank for the first time during the pandemic in a sign people are starting to return to work, even as millions more Americans filed for unemployment benefits.Continuing claims, which tally Americans’ ongoing benefits in state programs, fell to 21.1 million for the week ended May 16, Labor Department figures showed Thursday. Initial jobless claims for regular state programs totaled 2.12 million in the week ended May 23, to bring the 2 1/2-month total above 40 million.Separate data showed that U.S. orders for durable goods sank sharply for a second month in April as the pandemic wreaked havoc on the manufacturing industry.Johnson to Set Out Results of U.K. Virus Response Review (8:51 a.m. NY)“The Prime Minister will be able to set out later what we have concluded as a result of that review and to talk in some more detail about the recovery plan and what the next steps are likely to be,” Boris Johnson’s official spokesman, James Slack, said on a call with reporters Thursday.Johnson will speak at a 5 p.m. press conference with Chief Medical Officer Chris Whitty and Chief Scientific Adviser Patrick Vallance. The prime minister’s office also dismissed a police finding that Dominic Cummings, Johnson’s top aide, may have broken lockdown rules, insisting the matter is now closed.Separately, the U.K.’s coronavirus tracing program was hit by technical problems on the day of its launch, with some health-care workers unable to log on to the system. The so-called Test and Trace service is a key part of Johnson’s plan to help the British economy return to normality.AstraZeneca Joins With Oxford Biomedica to Produce Shot (8:33 a.m. NY)AstraZeneca Plc joined forces with Oxford Biomedica Plc to help produce one of the world’s fastest-moving potential vaccines against Covid-19. Oxford Biomedica will produce multiple batches of the vaccine this year and give AstraZeneca access to its Oxbox manufacturing center, according to a statement Thursday. AstraZeneca has been working with the University of Oxford on the inoculation.Third of Russians Believe Threat Is Overblown: Poll (8:26 a.m. NY)Nearly a third of Russians believe that the threat from the coronavirus crisis has been massively overblown, according to an opinion poll published on Thursday. The survey of 7,600 people from across Russia was conducted on May 21-26 by the Higher School of Economics in Moscow.Harrods Set to Reopen (7 a.m. NY)Luxury British retailer Harrods is set to reopen its flagship London store in June, with “significant” social distancing measures in place, and unveiled plans to open an outlet shop to sell stock left over from the season.The company plans to use footfall monitoring technology to limit capacity at its main Knightsbridge store and ensure social distancing can be maintained. Specific doors will be designated for entering and exiting the store, which was closed in March as the coronavirus outbreak started to spread in Britain.The new concept store, based in West London’s Westfield mall, has been designed to allow more space for customers, the company said. “In the new world in which we find ourselves, the economy needs businesses willing to look at its business model and current operations and think differently to enable growth, while protecting its customers and employees,” Managing Director Michael Ward said. “Harrods Outlet allows us to enable better social distancing across a larger footprint.”WHO Warns Against Austerity (6:37 a.m. NY)The World Health Organization warned against austerity in health spending as Europe’s economies reel from the effects of lockdowns to rein in the coronavirus. “We must learn from the mistakes of the past,” when public spending on health fell in the wake of the euro crisis, Hans Kluge, WHO regional director for Europe, said in a briefing.Cuts in public spending on health shift costs to households who may already be facing financial insecurity, the WHO’s European office warned. Kluge called for solidarity among European governments. “If there’s something we have learned so far it’s that one country, even if it’s doing a great job, is not standing alone. We are safe only when everyone is safe.”‘Safer’ for BOE to Err With Too Much Easing (6:22 a.m. NY)It’s safer for the Bank of England to ease too much rather than too little as it responds to the coronavirus pandemic, according to policy maker Michael Saunders. The U.K. is at risk of a relatively slow recovery from the crisis, which could prove especially damaging, Saunders said on a webinar Thursday. Failing to add more stimulus now could see the economy slip into a “lowflation trap.”“The costs of policy error are, to an extent, asymmetric at present,” he said. “It is safer to err on the side of easing somewhat too much, and then if necessary tighten as capacity pressures eventually build, rather than ease too little and find the economy gets stuck in a low-inflation rut.” The pound slid after the comments and money markets moved to price in a 10 basis-point interest-rate cut for May 2021. That would take the key rate to zero.Synthetic Bio Pioneer Ginkgo Raises $70 Million (6 a.m. NY)Ginkgo Bioworks Inc. has raised $70 million in an effort to build out DNA-based Covid-19 testing on a massive scale. The firm is best known for its efforts to design, modify and manufacture organisms to make industrial processes cheaper and more efficient — for example, it’s working to help program bacteria for treatments as living medicines. Now, Gingko is looking to repurpose the DNA-sequencing and automation infrastructure it developed to read and modify living cells to help address the nation’s shortfall of diagnostic testing.The U.S. has vastly scaled up its testing and is now processing somewhere between 300,000 and 450,000 each day, according to The COVID Tracking Project, a volunteer initiative to compile virus data. But those numbers still fall far short of the tens of millions that some experts have suggested are needed daily to reopen the economy safely and return to a new normal.DNA sequencing, Gingko is betting, might allow those efforts to scale up far more rapidly and cheaply to help achieve that end. The company is worth about $4.2 billion, based on a September effort that raised $290 million. The latest round includes investors such as DNA-sequencing giant Illumina Inc.Google Launches ‘Scam Spotter’ (6 a.m. NY)Alphabet Inc.’s Google has created “Scam Spotter” in partnership with Cybercrime Support Network, an organization that supports victims of online crimes. The website is intended to simplify and organize expert advice about coronavirus-related scams. Scammers have taken advantage of “fear and uncertainty,” around the virus, leading to approximately $40 million in fraud losses, Google said.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • ‘It would be extremely optimistic’ to see a vaccine by the end of the year: John Hopkins Infectious Diseases Expert
    Yahoo Finance Video

    ‘It would be extremely optimistic’ to see a vaccine by the end of the year: John Hopkins Infectious Diseases Expert

    U.S. cases for coronavirus reached more that 1.69 million, with at least 100,442 deaths from the virus. Dr. Amesh A. Adalja from Johns Hopkins’ Center for Health Security joins The Final Round to discuss the latest about the coronavirus, reopening the United States and the vaccine race.

  • Coronavirus update: U.S. marks grim milestone as Trump preps executive order on social-media companies
    MarketWatch

    Coronavirus update: U.S. marks grim milestone as Trump preps executive order on social-media companies

    The U.S. death toll from the coronavirus that causes COVID-19 rose above 101,000 on Thursday, one day after it exceeded the 100,000 level, a grim marker for the nation with the highest number of cases and deaths in the world.

  • TheStreet.com

    Roche and Gilead Sciences Testing Two-Drug Covid-19 Combo

    Roche and Gilead Sciences are kicking off a late-stage trial of a two-drug combination they hope will prove effective in treating Covid-19.

  • The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer
    Benzinga

    The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer

    Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 27) * ADC Therapeutics SA (NYSE: ADCT) (went public May 15) * Aeglea Bio Therapeutics Inc (NASDAQ: AGLE) * argenx SE - ADR (NASDAQ: ARGX) * ChemoCentryx Inc (NASDAQ: CCXI) * Imara Inc NASDAQ: (IMRA) * Immunovant Inc (NASDAQ: IMVT) * Mersana Therapeutics Inc (NASDAQ: MRSN) (announced positive interim Phase 1 data for XMT-1536 in patients with ovarian cancer) * Vermillion, Inc. (NASDAQ: VRML)Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 27) * Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) (announced publication of positive data for its antibiotic in treating bacteremia and endocarditis) * Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONN) * Teligent Inc (NEW JERSEY) (NASDAQ: TLGT)Stocks In Focus PhaseBio Gets FDA Nod For Potentially Pivotal Trial Of COVID-19 Treatment PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) announced FDA authorization to proceed with VANGARD, a potentially pivotal clinical trial to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome.PhaseBio said it expects to begin dosing patients by the end of June and report trial results late in the fourth quarter of 2020.The stock was jumping 54.3% to $6.82 in Thursday's premarket session.Roche To Commence Late-Stage Study Of COVID-19 Combo Treatment Option With Gilead's Remdesivir Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) announced the initiation of a global Phase 3 study to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir versus placebo plus remdesivir in hospitalized patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc. (NASDAQ: GILD).Roche aid it expects to enroll patients in the study in June, with the results likely to be available in the summer.Separately, Roche announced European approval of a new, shorter 2-hour Ocrevus infusion time, dosed twice yearly, for relapsing or primary progressive multiple sclerosis.Tetraphase Receives Sweetened Offer From Melinta After AcelRx's Revised Offer Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) said its board has received a revised proposal from Melinta amending its prior acquisition proposal. In light of the amended offer, Tetrephase said the Melinta offer is a superior offer.Tetraphase said it has notified AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) of the amended Melinta proposal, the superior offer determination and its intention to consider changing its recommendation or terminating the AcelRx offer unless AcelRx proposes revisions to the terms on or prior to Monday, June 1.This follows AccelRx sweetening its earlier offer to $30 million in stock and cash based on the AcelRx closing share price on May 22, plus an additional $14.5 million in contingent value rights payable in cash. See also: The Week Ahead In Biotech: ASCO Presentations In The Spotlight Aerpio To Collaborate With Quantum Leap In COVID-19 Drug Trial Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) and Quantum Leap Healthcare announced an agreement to evaluate razuprotafib in a new randomized, investigational treatment arm in the I-SPY COVID Trial for the treatment of ARDS in adult patients with moderate-to-severe COVID-19.The stock jumped 38.11% to $1.08 in after-hours trading.I-Mab's Severe COVID-19 Treatment Candidate Found Safe, Well-Tolerated In Phase 1b/2 Study I-Mab ADR (NASDAQ: IMAB) announced interim results from a clinical study of TJM2 in patients with cytokine release syndrome associated with severe COVID-19, with the Part 1 portion of the study evaluating the safety and tolerability of TJM2 in a total of 24 patients who were randomized at a ratio of 1:1:1 to receive either a single dose of 3 mg/kg TJM2, a single dose of 6 mg/kg TJM2 or placebo, administered by intravenous infusion.The company noted that a Data Monitoring Committee that evaluated data from Part 1 of the study concluded that it can commence the Part 2 of the study as planned, indicating TJM2 is safe and well-tolerated in the severe COVID-19 patients.The stock added 3.01% to $24.98 in after-hours trading.New Immunomedics CEO Quits Due To Coronavirus-Related Logistics Issues Immunomedics, Inc. (NASDAQ: IMMU) said CEO Harout Semerjian has decided to step down from his role effective immediately. Semeriian assumed the CEO role April 16 after his predecessor quit in the wake of a CRL for the company's lead antibody-drug conjugate sacituzumab govitecan and accusations regarding a data integrity breach.View more earnings on IBBThe company said the move was precipitated by the unfortunate significant logistical obstacles presented by the COVID-19 pandemic, including Semerjian's ability to fully assume his duties as CEO.Dr. Behzad Aghazadeh, executive chairman of Immunomedics, will continue to support the in an executive leadership role going forward, the company said.The stock was down 1.96% to $33.50 in the premarket session. FDA Grants Moleculin's Pre-IND Meeting Request For Coronavirus Drug Candidate, Shares to Resume TradingMoleculin Biotech, Inc., (NASDAQ: MBRX) said the FDA has granted the company's request for a pre-IND meeting to provide guidance regarding its plan to study its drug candidate WP1122 in a clinical trial for patients with COVID-19.The company said it plans to submit its IND application in the second half of the year, contingent on the guidance received from its pre-IND meeting with the FDA.Moleculin said in a separate release that Nasdaq has said its shares, which have been halted since May 4 due to questions regarding accuracy of information in the marketplace about its drug candidate for coronavirus, will begin trading again Thursday.Offerings Iovance Biotherapeutics Inc (NASDAQ: IOVA) said it intends to offer $500 million of its common stock, subject to market and other conditions, in an underwritten public offering. All of the shares in the offering are to be sold by the company.The stock was down 12.05% to $33.50 in Thursday's premarket session.BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) priced its underwritten public offering of 18.71 million shares at $4.50 per share. The company also said it is offering to certain investors pre-funded warrants to purchase up to an aggregate of 3.51 million shares of its common stock at $4.49 per pre-funded warrant.The company expects to raise gross proceeds of $100 million from the offering.The stock was down 7.25% at $4.67 premarket. Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) said it intends to offer in an underwritten public offering and subject to market and other conditions, $250 million worth of its common stock. All of the shares are being offered by the company.Arena shares were down 12.45% at $50.90 premarket. Arcus Biosciences Inc (NYSE: RCUS) said it has commenced an underwritten public offering of its common stock. All the shares in the offering will be sold by the company.The stock was down 1.29% at $26.70 premarket Thursday.On The Radar Earnings * Adverum Biotechnologies Inc (NASDAQ: ADVM) (after the close) * Geron Corporation (NASDAQ: GERN) (after the close)Related Link: Merck's Coronavirus Plan Of Attack: 2 Partnerships, M&A Deal Aimed At Treatment, Vaccine Development See more from Benzinga * The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Roche mixes Actemra with Gilead's remdesivir in COVID-19 trial
    Reuters

    Roche mixes Actemra with Gilead's remdesivir in COVID-19 trial

    Roche plans to test if mixing its anti-inflammation drug Actemra with Gilead Sciences Inc's anti-viral treatment remdesivir works better against severe COVID-19 pneumonia than remdesivir alone, the Swiss drugmaker said on Thursday. Actemra and remdesivir are being used separately in some settings and clinical trials, with the former drug used to tackle massive immune reactions that sometimes occur in patients stricken with the new coronavirus and the latter aimed at interfering with viral replication.

  • GlobeNewswire

    Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time approved in Europe

    Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced European Medicines Agency (EMA) approval of a new, shorter two-hour OCREVUS® (ocrelizumab) infusion time, dosed twice yearly, for relapsing or primary progressive multiple sclerosis (MS). “The approval of a shorter, two-hour infusion time for OCREVUS in Europe, dosed twice yearly, will further improve the treatment experience for patients while also increasing capacity in healthcare systems,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development.

  • GlobeNewswire

    Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia

    Roche is also close to completing enrolment of a global randomised, double-blind, placebo-controlled phase III clinical trial of Actemra®/RoActemra® (tocilizumab) in hospitalised patients with severe COVID-19 pneumonia (COVACTA), with results expected this summer. Basel, 28 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir, versus placebo plus remdesivir in hospitalised patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc.

  • Genentech Initiates Phase III Clinical Trial of Actemra Plus Remdesivir in Hospitalized Patients With Severe COVID-19 Pneumonia
    Business Wire

    Genentech Initiates Phase III Clinical Trial of Actemra Plus Remdesivir in Hospitalized Patients With Severe COVID-19 Pneumonia

    Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the initiation of a global Phase III, randomized, double-blind, multicenter study (REMDACTA) to evaluate the safety and efficacy of Actemra® (tocilizumab) plus the investigational antiviral remdesivir, versus placebo plus remdesivir in hospitalized patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc.

  • Rising Swiss rivalry as Roche and Novartis target same diseases
    Reuters

    Rising Swiss rivalry as Roche and Novartis target same diseases

    Swiss drugmakers Roche and Novartis released data on Wednesday on treatments aimed at winning sales from each other in eye disease and multiple sclerosis, in a sign of rising rivalry. Facing each other across the Rhine in Basel, the drugmakers have clashed and cooperated over the years, but their latest products point to more direct competition. Roche <ROG.S> Chief Executive Severin Schwan is looking beyond cancer drugs to fresh treatment areas, while Novartis <NOVN.S> CEO Vas Narashiman bulks up in the same territory.

  • Port Delivery System With Ranibizumab Shows Positive Phase III Results in Neovascular Age-Related Macular Degeneration
    Business Wire

    Port Delivery System With Ranibizumab Shows Positive Phase III Results in Neovascular Age-Related Macular Degeneration

    Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the Phase III Archway study, evaluating Port Delivery System with ranibizumab (PDS) in people living with neovascular or "wet" age-related macular degeneration (nAMD). PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customized formulation of ranibizumab over a period of months. The Archway trial met its primary endpoint, demonstrating that patients with PDS who received refills every six months achieved visual acuity outcomes equivalent to those receiving monthly ranibizumab 0.5 mg injections. In Archway, PDS was generally well-tolerated with a favorable benefit-risk profile.

  • GlobeNewswire

    Roche’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration

    Port Delivery System with ranibizumab (PDS) is a permanent refillable eye implant that continuously delivers ranibizumab over a period of months, potentially reducing the.

  • Anti-anxiety medication prescriptions have spiked 34% during the coronavirus pandemic
    MarketWatch

    Anti-anxiety medication prescriptions have spiked 34% during the coronavirus pandemic

    The coronavirus is taking a toll on mental health. The number of prescriptions for antidepressant, anti-anxiety and anti-insomnia medications filled per week increased 21% between Feb. 16 and March 15, 2020, according to a recent report by Express Scripts, a Cigna-owned (CI) pharmacy benefit manager. The study analyzed prescription claims filled between Jan. 19 and March 15 of this year among a sample of more than 31.5 million commercially-insured individuals, and found that claims peaked during the week ending March 15, when the novel coronavirus that causes COVID-19 was declared a pandemic.